Quality of care for older patients with cancer in the Veterans health administration versus the private sector

Annals of Internal Medicine

Volumn 154, Issue 11, 2011, Pages 727-736

  Keating, Nancy L ^a   Landrum, Mary Beth ^a   Lamont, Elizabeth B ^a   Bozeman, Samuel R ^b   Krasnow, Steven H ^c   Shulman, Lawrence N ^d   Brown, Jennifer R ^d   Earle, Craig C ^e   Oh, William K ^f   Rabin, Michael ^d   McNeil, Barbara J ^d  

^a Department of Health Care Policy ^*  (United States)

^b ABT ASSOCIATES   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COLON CANCER; COMORBIDITY; CONTROLLED STUDY; HEALTH CARE; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HOSPITAL; HUMAN; LARGE CELL LYMPHOMA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICARE; MULTIPLE MYELOMA; MYELOMA; NEOPLASM; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PRIVATE HOSPITAL; PROPENSITY SCORE; PROSTATE CANCER; SENSITIVITY ANALYSIS;

EID: 79958152924     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-11-201106070-00004     Document Type: Article

References (44)

1. Kizer KW, Demakis JG, Feussner JR. Reinventing VA health care: systematizing quality improvement and quality innovation. Med Care. 2000;38:I7-16. [PMID: 10843266]
2. Kizer KW, Dudley RA. Extreme makeover: Transformation of the veterans health care system. Annu Rev Public Health. 2009;30:313-39. [PMID: 19296778]
3. Landrum MB, Guadagnoli E, Zummo R, Chin D, McNeil BJ. Care following acute myocardial infarction in the Veterans Administration Medical Centers: a comparison with Medicare. Health Serv Res. 2004;39:1773-92. [PMID: 15533186]
4. Petersen LA, Normand SL, Daley J, McNeil BJ. Outcome of myocardial infarction in Veterans Health Administration patients as compared with medicare patients. N Engl J Med. 2000;343:1934-41. [PMID: 11136265]
5. Petersen LA, Normand SL, Leape LL, McNeil BJ. Regionalization and the underuse of angiography in the Veterans Affairs Health Care System as compared with a fee-for-service system. N Engl J Med. 2003;348:2209-17. [PMID: 12773649]
6. Asch SM, McGlynn EA, Hogan MM, Hayward RA, Shekelle P, Rubenstein L, et al. Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med. 2004;141:938-45. [PMID: 15611491]
7. Jha AK, Perlin JB, Kizer KW, Dudley RA. Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Engl J Med. 2003;348:2218-27. [PMID: 12773650]
8. Wilson NJ, Kizer KW. Oncology management by the "new" Veterans Health Administration. Cancer. 1998;82:2003-9. [PMID: 9587098]
9. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-48. [PMID: 8336512]
10. National Cancer Institute. Surveillance, Epidemiology, and End Results. Overview of the SEER Program. Accessed at http://seer.cancer.gov/about/overview.html on 11 April 2011.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83. [PMID: 3558716]
12. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-67. [PMID: 11146273]
13. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Prostate cancer. Version 1.2001. 2001. Accessed at www.nccn.org/professionals/physician_gls/f_guidelines.asp on 11 April 2011.
14. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon cancer. Version 1.2001. 2001. Accessed at www.nccn.org/professionals/physician_gls/f_guidelines.asp on 11 April 2011.
15. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Rectal cancer. Version 1.2001. 2001. Accessed at www.nccn.org/professionals/physician_gls/f_guidelines.asp on 11 April 2011.
16. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Lung cancer. Version 1.2001. 2001. Accessed at www.nccn.org/professionals/physician_gls/f_guidelines.asp on 11 April 2011.
17. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Multiple myeloma. Version 1.2001. 2001. Accessed at www.nccn.org/professionals/physician_gls/f_guidelines.asp on 11 April 2011.
18. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235-46. [PMID: 9052476]
19. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353:267-72. [PMID: 9929018]
20. Huggins C, Hodges CV. Studies on prostate cancer. I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-97.
21. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-33.
22. Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer. 2004;43:223-40. [PMID: 14739044]
23. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med. 2006;355:1583-91. [PMID: 17035651]
24. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, et al; National Comprehensive Cancer Network. NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park). 2000;14:111-9. [PMID: 11195405]
25. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-93. [PMID: 8559201]
26. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42. [PMID: 11807147]
27. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328:1002-6. [PMID: 7680764]
28. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335:1785-91. [PMID: 8965890]
29. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17: 2265-81. [PMID: 9802183]
30. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-24.
31. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006;163:262-70. [PMID: 16371515]
32. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14:680-6. [PMID: 14569183]
33. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998;54: 948-63. [PMID: 9750244]
34. Rosenbaum PR, Rubin DB. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcomes. J R Statist Soc. 1983; 45:212-18.
35. Vanderweele TJ, Arah OA. Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders. Epidemiology. 2011;22:42-52. [PMID: 21052008]
36. Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, et al. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003;95:1370-5. [PMID: 13130112]
37. Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, et al. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010;28:215-21. [PMID: 19933919]
38. Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010;303:1037-45. [PMID: 20233821]
39. Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:620-7. [PMID: 20038726]
40. Rogers SO Jr, Gray SW, Landrum MB, Klabunde CN, Kahn KL, Fletcher RH, et al. Variations in surgeon treatment recommendations for lobectomy in early-stage non-small-cell lung cancer by patient age and comorbidity. Ann Surg Oncol. 2010;17:1581-8. [PMID: 20162461]
41. Pearson S, Ladapo J, Prosser L. Institute for Clinical and Economic Review. Intensity modulated radiation therapy (IMRT) for localized prostate cancer. 2007. Accessed at www.icer-review.org/index.php/imrt.html on 10 May 2010.
42. Wilt TJ, Shamliyan TA, Taylor B, MacDonald R, Tacklind J, Rutks I. Comparative effectiveness of therapies for clinically localized prostate cancer. Comparative Effectiveness Review No. 13. Minnesota Evidence-based Practice Center; 2008. AHRQ contract no. 290-02-0009.
43. Keating NL, Landrum MB, Klabunde CN, Fletcher RH, Rogers SO, Doucette WR, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol. 2008;26:2532-7. [PMID: 18487570]
44. Lamont E, Landrum MB, Keating N, McNeil BJ. Evaluating colorectal cancer care in the Veterans Health Administration: How good are the data? J Geriatri Oncol. 2011. [Forthcoming]